Acumen was founded to advance a new way of understanding and treating Alzheimer’s disease. With a laser focus on this goal, we have a new class of targeted therapy in advanced development and are preparing to enter the clinic soon. Join us on this journey of discovery.

Acumen is forging a new path to treat neurodegenerative disorders by targeting the most toxic forms of the amyloid-beta protein that are now widely recognized as the primary triggers of Alzheimer’s disease. We have conducted extensive pre-clinical research demonstrating safety and efficacy of our lead drug candidate ACU193. We expect to initiate clinical trials in 2020.